Healthcare Sep 03, 2021 05:42 PM (GMT+8) · EqualOcean
On September 3, 2021, Nuo Cheng Jianhua (HK: 09969) and konoya (HK: 02162) signed a strategic cooperation agreement at 2021 China International Service Trade Fair to deepen their R & D cooperation and develop first in class macromolecular innovative drugs. As early as July, the application for clinical trial of CD20 x CD3 double antibody cm355 developed by Nuo Chengjianhua and konoya joint venture Tiannuo Jiancheng was accepted by nmpa, which is the first bispecific antibody new drug of konoya / Nuo Chengjianhua.